Harvard Bioscience, Inc. (HBIO)

Market Cap	26.89M
Revenue (ttm)	94.14M
Net Income (ttm)	-12.41M
Shares Out	44.07M
EPS (ttm)	-0.28
PE Ratio	n/a
Forward PE	13.56
Dividend	n/a
Ex-Dividend Date	n/a

Volume	351,742
Open	0.6000
Previous Close	0.6001
Day's Range	0.5900 - 0.6133
52-Week Range	0.5600 - 4.7000
Beta	1.47
Analysts	Buy
Price Target	4.50 (+637.71%)
Earnings Date	Mar 12, 2025

About HBIO

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems f...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Dec 7, 2000
• Employees: 355
• Stock Exchange: NASDAQ
• Ticker Symbol: HBIO
• Website: https://www.harvardbioscience.com

Financial Performance

In 2024, Harvard Bioscience's revenue was $94.14 million, a decrease of -16.14% compared to the previous year's $112.25 million. Losses were -$12.41 million, 263.3% more than in 2023.

Analyst Forecast

According to one analyst, the rating for HBIO stock is "Buy" and the 12-month stock price forecast is $4.5.

Price Target

$4.5

(637.71% upside)

Analyst Consensus: Buy